修复基因XRCC4多态性与膀胱癌易感性的Meta分析  

Association between polymorphisms in XRCC4 and bladder cancer risk:A Meta-analysis

作　　者：张万生[1] 王立国[1] 郭彬彬[1] 于航[1] 韩冬[1] 

机构地区：[1]吉林医药学院附属医院泌尿外科,吉林吉林132013

出　　处：《现代泌尿外科杂志》2016年第9期676-680,共5页Journal of Modern Urology

摘　　要：目的探讨XRCC4单核苷酸多态性与膀胱癌发病易感性的关联。方法通过检索PubMed、CNKI和万方数据库，检索从1960年1月1日至2015年12月31日国内外已经公开发表的中、英文献，筛选合格文献行Meta分析。结果最终纳入关于XRCC4基因多态性与膀胱癌易感性关联的病例-对照研究10项，计病例组2689例，对照组2915例。Meta分析结果显示，XRCC4基因rs28360317和rs1805377多态性位点与膀胱癌显著相关（rs28360317：BmA：OR=1．339，95％CI：1．088～1．649，P=0．006；BBvs．AA：OR=1．729，95％CI：1．137-2．629，P=0．010；BBvs．BA＋AA：OR=1．638，95％CI：1．144-2．346，P=0．007；rs1805377：BAvs．AA：OR=1．242，95％CI：1．041-1．482，P=0．016；BA＋BBvs．AA：OR=1．216，95％CI：1．023-1．445，P=0．027。以种族为依据的亚组分析揭示，XRCC4基因rs1805377多态性在高加索人群中与膀胱癌发病显著相关：B：OA：OR=1．295，95％CI：1．070-1．566，P=0．008；BAvs．AA：OR=1．362，95％CI：1．101-1．684，P=0．004；BA＋BBvs．AA：OR=1．348，95％CI：1．096-1．659，P-0．005。然而，XRCC4基因rs6869366和rs28360071多态性位点与膀胱癌的易感性无关。结论XRCC4基因rs28360317和rs1805377单核苷酸多态性与膀胱癌发病风险呈显著正相关，可作为膀胱癌患者潜在诊断、筛查分子标志物。Objective To explore the relevance between XRCC4 polymorphisms and bladder cancer risk in Asian popula- tion. Methods We retrieved PubMed, CNKI and Wanfang databases to search for all eligible studies published from Jan. 1, 1960 to Oct. 31, 2015 （restricted to English and Chinese） to conduct a Meta-analysis. Results A total of 10 case-control studies were enrolled, including 2 689 cases and 2 915 controls. Our work demonstrated that rs28360317 and rs1805377 poly- morphisms in XRCC4 significantly associated with bladder cancer risk： （rs28360317： B vs. A： OR=1. 339, 95%CI： 1,088- 1.649,P=0.006; BB vs. AA：OR=1.729, 95%CI：1.137-2.629,P=0.010; BB vs. BA＋AA：OR=1.638, 95%CI：1.144 -2.346,P=0.007; rs1805377： BAvs. AA：OR： 1.242, 95%CI：1.041-1.482,P=0.016; BA＋BB vs. AA： OR：1.216, 95 % CI ： 1. 023- 1. 445, P=0. 027）. In the stratification analysis by ethnicity, we identified an increased risk of rs1805377 polymorphism and bladder cancer risk in Caucasian population ： （B vs. A： OR =1. 295, 95 % CI ：1. 070- 1. 566, P=0. 008 ; BA vs. AA：OR=1. 362, 95%CI：1.101-1.684, P-=0.004; BA＋BB vs. AA：OR=1.348,95%CI：1.096-1.659,P=O.006）. How ever, no association was identified between rs6869366 and rs28360071 polymorphisms in XRCC4 and bladder cancer risk. Conclusions There is a positive relevance between rs28360317 and rs1805377 polymorphisms and bladder cancer risk, which can serve as a diagnosis and screening molecular biomarker for bladder cancer patients.

关 键 词：膀胱癌 XRCC4 易感性 META分析 

分 类 号：R737.14[医药卫生—肿瘤]